CN113939289A - 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 - Google Patents

一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 Download PDF

Info

Publication number
CN113939289A
CN113939289A CN202080042382.8A CN202080042382A CN113939289A CN 113939289 A CN113939289 A CN 113939289A CN 202080042382 A CN202080042382 A CN 202080042382A CN 113939289 A CN113939289 A CN 113939289A
Authority
CN
China
Prior art keywords
oral solid
solid tablet
tablet
mass
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080042382.8A
Other languages
English (en)
Inventor
仇罡
沈一唯
范文源
徐铄
吕会茹
卞佳琳
杜争鸣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiji Shenzhou Switzerland Co ltd
Original Assignee
Baiji Shenzhou Switzerland Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baiji Shenzhou Switzerland Co ltd filed Critical Baiji Shenzhou Switzerland Co ltd
Publication of CN113939289A publication Critical patent/CN113939289A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

提供了一种含有(S)‑7‑[4‑(1‑丙烯酰基哌啶)]‑2‑(4‑苯氧基苯基)‑4,5,6,7‑四氢吡唑并[1,5‑a]嘧啶‑3‑甲酰胺的口服固体片剂及其制备方法。所述口服固体片剂具有良好的药物释放特性，且用药方便，释放迅速高效，对设备无特殊要求，制剂工艺简单，能够保证制剂稳定性，便于运输和储藏，适合规模化生产。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN202080042382.8A 2019-06-10 2020-06-10 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 Pending CN113939289A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019090541 2019-06-10
CNPCT/CN2019/090541 2019-06-10
PCT/CN2020/095352 WO2020249001A1 (zh) 2019-06-10 2020-06-10 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法

Publications (1)

Publication Number Publication Date
CN113939289A true CN113939289A (zh) 2022-01-14

Family

ID=73781786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080042382.8A Pending CN113939289A (zh) 2019-06-10 2020-06-10 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法

Country Status (6)

Country Link
US (2) US20220249491A1 (zh)
EP (1) EP3981399A4 (zh)
JP (1) JP2022538214A (zh)
CN (1) CN113939289A (zh)
TW (1) TW202112376A (zh)
WO (1) WO2020249001A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112057427A (zh) * 2019-06-10 2020-12-11 百济神州(苏州)生物科技有限公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112457403B (zh) 2013-09-13 2022-11-29 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
TWI760356B (zh) 2016-08-16 2022-04-11 英屬開曼群島商百濟神州有限公司 (ｓ)-７-(１-丙烯醯基六氫吡啶-４-基)-２-(４-苯氧基苯基)-４,５,６,７-四氫吡唑並［１，５-ａ]嘧啶-３-甲醯胺的晶型、其製備和用途
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530348A (zh) * 2016-02-19 2018-01-02 江苏恒瑞医药股份有限公司 一种含有jak激酶抑制剂或其可药用盐的药物组合物
WO2018033853A2 (en) * 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN108778281A (zh) * 2016-11-25 2018-11-09 江苏恒瑞医药股份有限公司 一种吡啶酮类衍生物药物组合物及其制备方法
WO2019183226A1 (en) * 2018-03-21 2019-09-26 Mei Pharma, Inc. Combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2989106T3 (en) 2013-04-25 2017-03-20 Beigene Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS
WO2016123504A1 (en) * 2015-01-30 2016-08-04 Pharmacyclics Llc Btk inhibitor combinations and multidrug-resistance
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN110087680B (zh) * 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
CA3108065A1 (en) * 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530348A (zh) * 2016-02-19 2018-01-02 江苏恒瑞医药股份有限公司 一种含有jak激酶抑制剂或其可药用盐的药物组合物
WO2018033853A2 (en) * 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN108778281A (zh) * 2016-11-25 2018-11-09 江苏恒瑞医药股份有限公司 一种吡啶酮类衍生物药物组合物及其制备方法
WO2019183226A1 (en) * 2018-03-21 2019-09-26 Mei Pharma, Inc. Combination therapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BEIGENE: "Efficacy and Safety of BGB-3111 in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", 《HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT03206918》 *
BEIGENE: "Efficacy and Safety of BGB-3111 in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", 《HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT03206918》, 2 July 2017 (2017-07-02) *
TAM C.S.等: "A Head-to-head Phase III Study Comparing Zanubrutinib Versus Ibrutinib in Patients with Waldenstrom macroglobulinemia", 《FUTURE ONCOLOGY》, vol. 14, no. 22, 5 June 2018 (2018-06-05), pages 2229 - 2237, XP055765166, DOI: 10.2217/fon-2018-0163 *
关志宇主编: "《药物制剂辅料与包装材料》", 中国医药科技出版社, pages: 87 *
百济神州（北京）生物科技有限公司: "评估BTK抑制剂BGB-3111在中国B淋巴细胞肿瘤患者的安全性、耐受性以及药代/药效动力学特征的I期临床研究", 《HTTP://WWW.CHINADRUGTRIALS.ORG.CN》 *
百济神州（北京）生物科技有限公司: "评估BTK抑制剂BGB-3111在中国B淋巴细胞肿瘤患者的安全性、耐受性以及药代/药效动力学特征的I期临床研究", 《HTTP://WWW.CHINADRUGTRIALS.ORG.CN》, 13 May 2016 (2016-05-13) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112057427A (zh) * 2019-06-10 2020-12-11 百济神州(苏州)生物科技有限公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法

Also Published As

Publication number Publication date
US20240075039A1 (en) 2024-03-07
US20220249491A1 (en) 2022-08-11
EP3981399A1 (en) 2022-04-13
TW202112376A (zh) 2021-04-01
EP3981399A4 (en) 2023-05-31
JP2022538214A (ja) 2022-09-01
WO2020249001A1 (zh) 2020-12-17

Similar Documents

Publication Publication Date Title
CN113939289A (zh) 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
KR101380088B1 (ko) 약학 조성물
JPWO2003082279A1 (ja) 単一の結晶形を含有する固形製剤
WO2017170858A1 (ja) 溶出性に優れた経口製剤
KR101977785B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
CA2662265A1 (en) Imatinib compositions
EP2285357A1 (en) Pharmaceutical compositions comprising brivaracetam
CA2874779C (en) Pharmaceutical composition of entecavir and process of manufacturing
WO2021238978A1 (zh) 含硝羟喹啉前药的药物组合物及其制备方法和应用
CN109875972B (zh) 一种奥美沙坦酯氨氯地平药物组合物
KR101834559B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 고형 복합제제
WO2006123213A1 (en) Modified release formulations of gliclazide
CN112057427A (zh) 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
JPH04159222A (ja) 経口投与用固形薬剤の製造方法
WO2020122244A1 (ja) 錠剤及びその製造方法
CA2014926A1 (en) Oral preparation
KR101944085B1 (ko) 발사르탄 함유 고형 경구제형 및 그 제조방법
WO2013182609A1 (en) Stable pharmaceutical compositions with a fast onset
WO2000010557A1 (fr) Preparations solides stabilisees
WO2024096838A1 (en) A pharmaceutical composition comprising solid dispersion of empagliflozin
TWI523842B (zh) 托伐普坦固體分散體及其製備方法
CN115212177A (zh) 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体刻痕片剂及其制备方法
CN114767641A (zh) 一种司替戊醇固体制剂及其制备方法
CN117797107A (zh) 一种枸橼酸西地那非药剂及其制备方法和应用
WO2024096839A1 (en) A pharmaceutical composition comprising solid dispersion of empagliflozin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination